Do analysts recommend NXL or NSPR?

InspireMD has a consensus target price of $4.50, suggesting a potential upside of 451.27%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to NXL or NSPR?

In the previous week, InspireMD had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for InspireMD and 1 mentions for Nexalin Technology. InspireMD's average media sentiment score of 0.50 beat Nexalin Technology's score of 0.00 indicating that InspireMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InspireMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SRTS or NXL?

Sensus Healthcare presently has a consensus target price of $6.88, indicating a potential upside of 155.58%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sensus Healthcare is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensus Healthcare 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SRTS or NXL?

In the previous week, Sensus Healthcare had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for Nexalin Technology. Sensus Healthcare's average media sentiment score of 0.62 beat Nexalin Technology's score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensus Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NXL or STRR?

Star Equity has a consensus price target of $28.00, indicating a potential upside of 161.68%. Given Star Equity's stronger consensus rating and higher probable upside, analysts plainly believe Star Equity is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Star Equity 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Does the media prefer NXL or STRR?

In the previous week, Star Equity had 7 more articles in the media than Nexalin Technology. MarketBeat recorded 8 mentions for Star Equity and 1 mentions for Nexalin Technology. Star Equity's average media sentiment score of 1.30 beat Nexalin Technology's score of 0.00 indicating that Star Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Star Equity 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NXL or NTRB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend NXL or TELA?

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 158.82%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is NXL or TELA more profitable?

TELA Bio has a net margin of -49.30% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -3,018.12% -191.88% -166.43% TELA Bio -49.30% -1,320.81% -55.83%

Nexalin Technology (NXL) Competitors

$0.50 -0.02 (-4.24%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$0.53 +0.03 (+5.08%)

As of 05:31 AM Eastern

Compare

NXL vs. NSPR, SRTS, STRR, NTRB, and TELA

Should you buy Nexalin Technology stock or one of its competitors? MarketBeat compares Nexalin Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nexalin Technology include InspireMD (NSPR), Sensus Healthcare (SRTS), Star Equity (STRR), Nutriband (NTRB), and TELA Bio (TELA). These companies are all part of the "medical equipment" industry.

How does Nexalin Technology compare to InspireMD?

Nexalin Technology (NASDAQ:NXL) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Nexalin Technology has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	34.40	-$8.22M	-$0.47	N/A
InspireMD	$10.85M	3.52	-$19.92M	-$0.73	N/A

In the previous week, InspireMD had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for InspireMD and 1 mentions for Nexalin Technology. InspireMD's average media sentiment score of 0.50 beat Nexalin Technology's score of 0.00 indicating that InspireMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InspireMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InspireMD has a consensus target price of $4.50, suggesting a potential upside of 451.27%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Nexalin Technology has a beta of 3.79, indicating that its share price is 279% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

InspireMD has a net margin of -413.96% compared to Nexalin Technology's net margin of -3,018.12%. InspireMD's return on equity of -69.42% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats Nexalin Technology on 11 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to Sensus Healthcare?

Sensus Healthcare (NASDAQ:SRTS) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by insiders. Comparatively, 25.3% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sensus Healthcare presently has a consensus target price of $6.88, indicating a potential upside of 155.58%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sensus Healthcare is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sensus Healthcare has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.79, indicating that its stock price is 279% more volatile than the broader market.

In the previous week, Sensus Healthcare had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for Nexalin Technology. Sensus Healthcare's average media sentiment score of 0.62 beat Nexalin Technology's score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sensus Healthcare has higher revenue and earnings than Nexalin Technology. Sensus Healthcare is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.61	-$7.72M	-$0.47	N/A
Nexalin Technology	$300K	34.40	-$8.22M	-$0.47	N/A

Sensus Healthcare has a net margin of -34.50% compared to Nexalin Technology's net margin of -3,018.12%. Sensus Healthcare's return on equity of -15.79% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-34.50%	-15.79%	-14.02%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Summary

Sensus Healthcare beats Nexalin Technology on 11 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Star Equity?

Nexalin Technology (NASDAQ:NXL) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Star Equity has a net margin of -4.18% compared to Nexalin Technology's net margin of -3,018.12%. Star Equity's return on equity of -4.04% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Star Equity	-4.18%	-4.04%	-2.40%

Nexalin Technology has a beta of 3.79, suggesting that its share price is 279% more volatile than the broader market. Comparatively, Star Equity has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

In the previous week, Star Equity had 7 more articles in the media than Nexalin Technology. MarketBeat recorded 8 mentions for Star Equity and 1 mentions for Nexalin Technology. Star Equity's average media sentiment score of 1.30 beat Nexalin Technology's score of 0.00 indicating that Star Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Star Equity	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by insiders. Comparatively, 10.4% of Star Equity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Star Equity has higher revenue and earnings than Nexalin Technology. Star Equity is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	34.40	-$8.22M	-$0.47	N/A
Star Equity	$172.16M	0.23	-$5.92M	-$2.63	N/A

Star Equity has a consensus price target of $28.00, indicating a potential upside of 161.68%. Given Star Equity's stronger consensus rating and higher probable upside, analysts plainly believe Star Equity is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

Star Equity beats Nexalin Technology on 12 of the 17 factors compared between the two stocks.

How does Nexalin Technology compare to Nutriband?

Nexalin Technology (NASDAQ:NXL) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nutriband has a net margin of -403.98% compared to Nexalin Technology's net margin of -3,018.12%. Nutriband's return on equity of -118.33% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Nutriband	-403.98%	-118.33%	-101.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nexalin Technology has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	34.40	-$8.22M	-$0.47	N/A
Nutriband	$2.04M	21.31	-$8.23M	-$2.60	N/A

Nexalin Technology has a beta of 3.79, meaning that its share price is 279% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, Nexalin Technology had 1 more articles in the media than Nutriband. MarketBeat recorded 1 mentions for Nexalin Technology and 0 mentions for Nutriband. Nexalin Technology's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Company	Overall Sentiment
Nexalin Technology	Neutral
Nutriband	Neutral

Summary

Nutriband beats Nexalin Technology on 7 of the 13 factors compared between the two stocks.

How does Nexalin Technology compare to TELA Bio?

Nexalin Technology (NASDAQ:NXL) and TELA Bio (NASDAQ:TELA) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Nexalin Technology has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	34.40	-$8.22M	-$0.47	N/A
TELA Bio	$80.28M	0.47	-$38.83M	-$0.79	N/A

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nexalin Technology has a beta of 3.79, indicating that its stock price is 279% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 158.82%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

TELA Bio has a net margin of -49.30% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
TELA Bio	-49.30%	-1,320.81%	-55.83%

In the previous week, Nexalin Technology had 1 more articles in the media than TELA Bio. MarketBeat recorded 1 mentions for Nexalin Technology and 0 mentions for TELA Bio. Nexalin Technology's average media sentiment score of 0.00 equaled TELA Bio'saverage media sentiment score.

Company	Overall Sentiment
Nexalin Technology	Neutral
TELA Bio	Neutral

Summary

Nexalin Technology beats TELA Bio on 8 of the 15 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$10.78M	$3.97B	$6.62B	$11.99B
Dividend Yield	N/A	2.15%	3.05%	5.58%
P/E Ratio	-1.07	42.47	28.06	23.74
Price / Sales	34.40	54.75	394.97	108.85
Price / Cash	N/A	38.92	22.86	37.25
Price / Book	2.51	4.64	5.75	6.78
Net Income	-$8.22M	$31.68M	$206.05M	$337.51M
7 Day Performance	-8.82%	-2.59%	-2.50%	-2.34%
1 Month Performance	42.31%	16.76%	6.65%	1.88%
1 Year Performance	-60.51%	21.08%	32.09%	25.55%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.1113 of 5 stars	$0.50 -4.2%	N/A	-61.1%	$10.78M	$300K	N/A	3
NSPR InspireMD	3.9918 of 5 stars	$1.01 +2.0%	$4.50 +345.5%	-67.3%	$47.31M	$10.85M	N/A	50	News Coverage Gap Down
SRTS Sensus Healthcare	4.0485 of 5 stars	$2.84 -0.4%	$6.88 +142.1%	-45.3%	$46.92M	$27.48M	N/A	40	Gap Up
STRR Star Equity	4.3405 of 5 stars	$11.59 -0.9%	$28.00 +141.6%	+402.3%	$43.26M	$172.16M	N/A	1,200	Positive News Gap Down
NTRB Nutriband	0.3538 of 5 stars	$3.55 flat	N/A	-53.6%	$43.15M	$2.04M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. NSPR, SRTS, STRR, NTRB, and TELA

How does Nexalin Technology compare to InspireMD?

Summary

How does Nexalin Technology compare to Sensus Healthcare?

Summary

How does Nexalin Technology compare to Star Equity?

Summary

How does Nexalin Technology compare to Nutriband?

Summary

How does Nexalin Technology compare to TELA Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. NSPR, SRTS, STRR, NTRB, and TELA

How does Nexalin Technology compare to InspireMD?

Which has better earnings and valuation, NXL or NSPR?

Does the media refer more to NXL or NSPR?

Do institutionals & insiders hold more shares of NXL or NSPR?

Do analysts recommend NXL or NSPR?

Which has more risk and volatility, NXL or NSPR?

Is NXL or NSPR more profitable?

Summary

How does Nexalin Technology compare to Sensus Healthcare?

Do institutionals & insiders believe in SRTS or NXL?

Do analysts recommend SRTS or NXL?

Which has more volatility and risk, SRTS or NXL?

Does the media prefer SRTS or NXL?

Which has preferable earnings and valuation, SRTS or NXL?

Is SRTS or NXL more profitable?

Summary

How does Nexalin Technology compare to Star Equity?

Is NXL or STRR more profitable?

Which has more volatility & risk, NXL or STRR?

Does the media prefer NXL or STRR?

Do institutionals and insiders hold more shares of NXL or STRR?

Which has better earnings & valuation, NXL or STRR?

Do analysts recommend NXL or STRR?

Summary

How does Nexalin Technology compare to Nutriband?

Do insiders & institutionals hold more shares of NXL or NTRB?

Is NXL or NTRB more profitable?

Do analysts prefer NXL or NTRB?

Which has stronger valuation and earnings, NXL or NTRB?

Which has more risk & volatility, NXL or NTRB?

Does the media prefer NXL or NTRB?

Summary

How does Nexalin Technology compare to TELA Bio?

Which has higher valuation and earnings, NXL or TELA?

Do insiders & institutionals have more ownership in NXL or TELA?

Which has more volatility and risk, NXL or TELA?

Do analysts recommend NXL or TELA?

Is NXL or TELA more profitable?

Does the media favor NXL or TELA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools